Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.57
- Piotroski Score 3.00
- Grade Equal-Weight
- Symbol (MOR)
- Company MorphoSys AG
- Price $18.96
- Changes Percentage (2.43%)
- Change $0.45
- Day Low $18.38
- Day High $19.15
- Year High $19.50
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 08/29/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.50
- Trailing P/E Ratio -11.97
- Forward P/E Ratio -11.97
- P/E Growth -11.97
- Net Income $-189,734,199
Income Statement
Quarterly
Annual
Latest News of MOR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Mortgage Refinance Rates Today: November 18, 2024 -- Rates Move Upward
Average mortgage refinance rates for 30-year fixed, 15-year fixed, and 20-year fixed loans are provided. Refinancing can help lower interest rates, reduce payments, or access home equity. Consider cos...
By Forbes | 16 hours ago -
Mortgage Rates Today: November 18, 2024 -- 15-Year and 30-Year Mortgage Rates Move Up
The current average mortgage rates are 7.29% for a 30-year fixed, 6.42% for a 15-year fixed, and 7.31% for a 30-year jumbo mortgage....
By Forbes | 16 hours ago -
AP Top 25 Extra Points: No. 16 Buffs double win total and look for more -- lots more, Sanders says
Colorado Buffaloes have achieved their highest ranking in eight years at No. 16 in the AP Top 25 college football poll. Coach Deion Sanders remains focused on the team's expectations and upcoming game...
By AP NEWS | 16 hours ago